One hundred and eight participants were enrolled, with ninety-nine completing all baseline assessments and subsequent randomisation to a study group (Fig. 1; descriptive data, Table 1). Seven participants withdrew during the six-month intervention.
Table 1
Descriptive baseline characteristics of study cohort
|
High-intensity
(n = 33)
|
Moderate-intensity
(n = 34)
|
Control
(n = 32)
|
Test statistic
|
Age, years
|
70.2 ± 5.3
|
68.4 ± 4.2
|
68.7 ± 5.9
|
F = 1.22
|
Gender, % Female (n)
|
51.5 (17)
|
52.9 (18)
|
59.4 (19)
|
χ2 = 0.79
|
APOE ε4 allele carriers, % (n)
|
27.3 (9)
|
23.5 (8)
|
28.1 (9)
|
χ2 = 0.90
|
BDNF Val66Met carriers, % (n)
|
33.3 (11)
|
32.4 (11)
|
50 (16)
|
χ2 = 2.70
|
Years of education
|
13.5 ± 2.2
|
14.2 ± 2.5
|
14.5 ± 2.1
|
F = 1.65
|
Global cognition, MoCA score
|
26.0 ± 2.1
|
26.4 ± 2.8
|
26.7 ± 2.0
|
F = 0.64
|
Baseline VO2peak (ml/kg/min)
|
22.2 ± 6.3
|
24.7 ± 6.9
|
22.8 ± 6.1
|
F = 1.36
|
Baseline peak power (W)
|
128.9 ± 49.4
|
145.0 ± 51.1
|
126.4 ± 37.1
|
F = 1.57
|
Alcohol, Units per week
|
5.7 ± 5.9
|
5.1 ± 5.5
|
6.4 ± 6.1
|
F = 0.44
|
Time from baseline to 6-mo assessment (wks)
|
33.0 ± 3.7
|
34.7 ± 4.7
|
34.1 ± 2.3
|
F = 1.60
|
Time from baseline to 18-mo assessment (wks)
|
85.3 ± 3.6
|
88.3 ± 5.6
|
87.1 ± 3.9
|
F = 3.38*
|
Physical activity (Met.min/wk− 1)
|
4379 ± 3708
|
4372 ± 2488
|
3533 ± 1981
|
F = 0.94
|
DASS Depression score
|
2.3 ± 3.0
|
1.61 ± 2.1
|
1.7 ± 1.9
|
F = 0.95
|
Daily kilojoule intakea
|
6709 ± 2459
|
7430 ± 3286
|
6059 ± 1896
|
F = 2.01
|
BMI (kg/m2)
|
25.8 ± 3.7
|
26.0 ± 3.9
|
25.3 ± 3.4
|
F = 0.30
|
Waist-hip ratio
|
0.87 ± 0.08
|
0.88 ± 0.07
|
0.88 ± 0.08
|
F = 0.08
|
*P < 0.05, post-hoc Tukey’s significant difference between high-intensity group and moderate-intensity group. Test statistics determined by one-way analysis of variance for continuous variables and chi-square for categorical variables. Abbreviations: APOE, Apolipoprotein E; BDNF Val66Met, brain-derived neurotrophic factor Valine66Methionine single nucleotide polymorphism; BMI, body mass index; DASS, Depression, Anxiety and Stress Scales; Met.min/wk− 1, metabolic minutes per week (subjective habitual physical activity measurement); MoCA, Montreal Cognitive Assessment; VO2peak, peak aerobic capacity (fitness measurement); W, wattage. aDaily kilojoule intake quantified from the Cancer Council of Victoria Food Frequency Questionnaire. |
Individuals excluded from the per-protocol analyses (n = 13; based on low adherence or withdrawal from study) reported higher education (15.3 ± 2.1 y), compared with those included (13.9 ± 2.3 y; t = 2.17, p < 0.05; eTable 1).
Adherence to prescribed intervention
There was no difference in exercise session attendance between the high-intensity (85.5 ± 12.4%) and moderate-intensity (86.3 ± 9.8%) groups.
The high-intensity group maintained 120.6 ± 25.1% of peak aerobic power during the high-intensity intervals, while the moderate-intensity group cycled continuously at 70.1 ± 16.3% of peak aerobic power.
There were no serious adverse events recorded.
Group comparisons
In both the intention-to-treat and per-protocol analyses, a time*group effect was observed for cardiorespiratory fitness, peak aerobic power, and body fat from pre- to post-intervention (Table 2). The high-intensity group experienced greater improvements in cardiorespiratory fitness (+ 24.3%) compared with the moderate-intensity group (+ 12.4%; B = 3.92, p < 0.01), and control group (+ 2.4%; B = 7.36, p < 0.001). The high-intensity group also experienced greater improvements in peak aerobic power (+ 29%; B = 55.62, p < 0.001) and decreases in percentage body fat (-3.5%; B = -1.59, p < 0.05), compared with the control group (peak power change, + 1.3%; percentage body fat change, 0.0%).
Table 2
Effects of the exercise interventions on physiological measures and cognitive composite scores
|
Raw mean change from baseline (95% CI)
|
Time*Group (ITT)
Unstandardized B (standard error)
|
Time*Group (PP)
Unstandardized B (standard error)
|
|
High-intensity
(n = 33)
|
Moderate-intensity
(n = 34)
|
Control
(n = 32)
|
Baseline to
6 months
|
All timepoints
|
Baseline to 6 months
|
All timepoints
|
VO2peak (ml/kg/min)
|
|
|
3.67 (0.72)**
|
0.35 (0.38)
|
3.76 (0.75)**
|
0.30 (0.40)
|
6
|
5.40 (4.00, 6.81)
|
3.02 (1.79, 4.25)
|
0.55 (-0.67, 1.77)
|
18
|
0.78 (-0.62, 2.18)
|
-1.43 (-2.78, -0.08)
|
-0.99 (-2.85, 0.86)
|
Peak power (Watts)
|
|
|
27.33 (4.24)**
|
3.18 (2.51)
|
28.89 (4.52)**
|
2.98 (2.66)
|
6
|
37.2 (29.4, 45.1)
|
29.5 (20.6, 38.4)
|
1.60 (-3.12, 6.33)
|
18
|
7.2 (-0.6, 15.1)
|
0.14 (-6.56, 6.85)
|
-9.59 (-16.7, -2.43)
|
% Body fat
|
|
|
-0.80 (0.37)*
|
-0.09 (0.23)
|
-0.94 (0.38)*
|
-0.02 (0.24)
|
6
|
-1.04 (-1.83, -0.25)
|
-0.48 (-1.05, 0.10)
|
0.00 (-0.64. 0.63)
|
18
|
1.73 (0.39, 3.07)
|
2.64 (1.85, 3.44)
|
1.97 (0.70, 3.24)
|
Global Cognitive composite
|
|
|
-0.04 (0.07)
|
-0.02 (0.03)
|
-0.01 (0.07)
|
-0.03 (0.23)
|
6
|
0.11 (-0.03, 0.24)
|
0.19 (0.09, 0.28)
|
0.13 (-0.02, 0.27)
|
18
|
0.18 (0.05, 0.30)
|
0.21 (0.07, 0.34)
|
0.23 (0.08, 0.38)
|
Executive Function composite
|
0.00 (0.09)
|
0.02 (0.04)
|
0.04 (0.09)
|
0.02 (0.04)
|
6
|
0.17 (-0.00, 0.34)
|
0.31 (0.14, 0.49)
|
0.13 (-0.03, 0.30)
|
18
|
0.30 (0.12, 0.47)
|
0.31 (0.06, 0.56)
|
0.18 (0.00, 0.35)
|
Episodic Memory composite
|
0.02 (0.11)
|
-0.04 (-0.04)
|
0.01 (0.11)
|
-0.06 (0.04)
|
6
|
0.19 (-0.04, 0.43)
|
0.15 (-0.00, 0.30)
|
0.13 (-0.07, 0.34)
|
18
|
0.20 (-0.04, 0.43)
|
0.25 (0.07, 0.44)
|
0.32 (0.12, 0.53)
|
Attention composite
|
0.01 (0.15)
|
-0.03 (0.05)
|
0.09 (0.16)
|
-0.02 (0.71)
|
6
|
-0.17 (-0.50, 0.15)
|
0.11 (-0.12, 0.35)
|
-0.22 (-0.48, 0.04)
|
18
|
-0.09 (-0.30, 0.13)
|
-0.02 (-0.26, 0.23)
|
-0.10 (-0.33, 0.13)
|
Intention-to-treat analyses, n = 99; Per-protocol analyses, n = 86. *p < 0.05, **p < 0.001. Baseline to 6 months is pre- to immediately post-intervention. ‘All timepoints’ includes the full study period of baseline, 6 months, and an 18-month follow-up (i.e. 12 months post-intervention). Abbreviations: CI, confidence intervals; ITT, Intention-to-treat analyses; PP, Per-protocol analyses ; VO2peak, peak aerobic capacity (fitness measurement). All models include age, gender, and years of education as covariates. |
There were no significant time*group effects on any of the cognitive composite scores. Main effects for time were significant for the executive function composite variable (p < 0.05), likely indicating a small practice effect experienced on the tasks assessing this cognitive domain. Similarly, there were no significant effects of the genotype*time*group interactions on the cognitive composite scores.
Individual variability analysis
Within the high-intensity group only, changes in cardiorespiratory fitness were associated with changes in global cognitive function (F = 4.91, p < 0.05, ηp2 = 0.18) and executive function (F = 13.89, p < 0.001, ηp2 = 0.37; Table 3). Increases in cardiorespiratory fitness were associated with improvements in global cognition (F = 4.37, p < 0.05, ηp2 = 0.06) and executive function (F = 4.83, p < 0.05, ηp2 = 0.06) from pre- to post- intervention in the whole sample.
Table 3
Changes in cardiorespiratory fitness (residuals) and cognitive function (residuals) from pre- to immediately post-intervention
|
Independent Variable (F statistic)
|
Dependent Variablea
|
High-intensity group
|
Whole cohort
|
Fitness changea
|
Fitness changea
|
Fitness changea x BDNF Val66Met
|
Fitness changea x APOE ε4 carriage
|
Global Cognition change
|
4.91*
|
4.37*
|
5.13*
|
2.50
|
Executive Function change
|
13.89**
|
4.83*
|
4.54*
|
0.33
|
Episodic Memory change
|
0.68
|
0.84
|
4.96*
|
2.57
|
Attention change
|
0.94
|
2.23
|
0.01
|
0.13
|
aResidualised change scores created from a linear model where the baseline score was entered as an independent variable and post score (6 months) as the dependent variable. *p < 0.05, **p < 0.001. Covariates: age, gender, years of education. Abbreviations: APOE, Apolipoprotein E; BDNF Val66Met, brain-derived neurotrophic factor Valine66Methionine single nucleotide polymorphism. |
The BDNF*fitness change interaction term was significant for global cognition (F = 5.13, p < 0.05, ηp2 = 0.07), executive function (F = 4.54, p < 0.05, ηp2 = 0.06), and episodic memory (F = 4.96, p < 0.05, ηp2 = 0.07). Post-hoc analyses of these interactions revealed non-Met carriers (i.e. BDNF Val/Val homozygotes) received benefit in terms of a relationship between change in cardiorespiratory fitness and global cognitive function (F = 7.52, p < 0.01, ηp2 = 0.16) and executive function (F = 8.83, p < 0.01, ηp2 = 0.18; Figs. 2A-C); i.e., greater improvements in cardiorespiratory fitness were associated with greater improvements in cognitive performance post-intervention among non-Met carriers.
We did not observe an effect of APOE*fitness change on any of the cognitive change scores (Table 3). However, following stratification by APOE ε4 carriage, only ε4 carriers demonstrated an association between increases in cardiorespiratory fitness and improvements in global cognition (F = 4.92, p < 0.05, ηp2 = 0.23; eFigure 2).